AIM ImmunoTech (AIM) Cash from Investing Activities (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Cash from Investing Activities came in at -$37000.0 in Q1 2026, down 104.12% YoY from $898000.0 in Q1 2025, and up 61.05% on a QoQ basis from -$95000.0 in Q4 2025.
AIM ImmunoTech (AIM) Cash from Investing Activities (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Cash from Investing Activities data on file, last reported at -$37000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 104.12% year-over-year to -$37000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $918000.0 (down 84.07% YoY) and the FY2025 annual result came in at $1.9 million, down 60.62% from the prior year.
- Cash from Investing Activities climbed to -$37000.0 in Q1 2026, from -$95000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $7.7 million in Q2 2022 to a low of -$346000.0 in Q1 2022.
- A 5-year average of $981058.8 and a median of $250000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 234.4% — and 2024, when it surged 1830.84%.
- Tracing AIM's Cash from Investing Activities over 5 years: stood at $3.4 million in 2022, then slumped by 106.36% to -$214000.0 in 2023, then surged by 1830.84% to $3.7 million in 2024, then tumbled by 102.56% to -$95000.0 in 2025, then surged by 61.05% to -$37000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$37000.0 (Q1 2026), -$95000.0 (Q4 2025), and $296000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | -112,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -112,000.00 |
| Jun 30, 2026 | -112,000.00 |
| Mar 31, 2026 | -37,000.00 |
| Mar 31, 2026 | -37,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Dec 31, 2025 | -95,000.00 |
| Sep 30, 2025 | 296,000.00 |
| Sep 30, 2025 | 296,000.00 |
| Jun 30, 2025 | 754,000.00 |
| Jun 30, 2025 | 754,000.00 |
| Mar 31, 2025 | 898,000.00 |
| Mar 31, 2025 | 898,000.00 |
| Dec 31, 2024 | 3.70 Mn |
| Dec 31, 2024 | 3.70 Mn |
| Sep 30, 2024 | 334,000.00 |
| Sep 30, 2024 | 334,000.00 |
| Jun 30, 2024 | 826,000.00 |
| Jun 30, 2024 | 826,000.00 |
| Mar 31, 2024 | -158,000.00 |
| Mar 31, 2024 | -158,000.00 |